@entity876 and @entity995 expression predict progression in T1 XXXX .

@entity1 @entity5 @entity876 @entity150 @entity204 @entity995
The optimal clinical management of minimally invasive (stage T1) @entity150 is controversial. T1 @entity150 share characteristics of both noninvasive (Ta) papillary @entity5 and high stage, muscle-invasive @entity150 . @entity1 with T1 @entity150 have a higher risk of @entity5 progression and @entity204 than do @entity1 with Ta @entity150 . However, this risk is much lower than that of @entity1 with high-stage @entity150 . Methods of identifying T1 @entity150 @entity1 at greatest risk for progression may significantly improve clinical management. We retrospectively evaluated two @entity5 suppressor genes, @entity876 and @entity995 , as potential prognostic markers for progression in a cohort of 45 @entity1 with pT1 @entity150 . Median follow-up for these individuals was greater than 3.5 years. Of this group, 58% had altered @entity876 expression based on positive @entity876 immunostaining. Three patterns for @entity995 nuclear protein staining were observed: absent, heterogeneous (normal), and strongly homogeneous. Progression-free survival was similar for @entity1 with loss of @entity995 protein expression and those with apparent overexpression of @entity995 protein. Therefore, both staining patterns were considered abnormal. @entity1 with normal expression of both proteins (i.e., @entity876 negative and @entity995 heterogeneously positive) had an excellent outcome, with no @entity1 showing disease progression, whereas @entity1 with abnormal expression of either or both proteins had a significant increase in progression (P = 0.04 and P = 0.005, respectively). These data support the stratification of T1 @entity150 @entity1 based on @entity876 and @entity995 nuclear protein status and suggest that @entity1 with normal protein expression for both genes can be managed conservatively, whereas @entity1 with alterations in one and particularly both genes require more aggressive treatment.
